HC Wainwright & Co. Reiterates Buy on Cullinan Oncology, Maintains $49 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Edward White reiterates a Buy rating on Cullinan Oncology (NASDAQ:CGEM) and maintains a $49 price target.
May 26, 2023 | 10:12 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Edward White reiterates a Buy rating on Cullinan Oncology (NASDAQ:CGEM) and maintains a $49 price target.
The news directly mentions Cullinan Oncology (NASDAQ:CGEM) and the analyst's Buy rating and maintained price target of $49. This reaffirmation of a positive rating by a reputable analyst is likely to have a positive short-term impact on the stock price, as it signals confidence in the company's prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100